Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Inactivated H1N1 Vaccine Clear all

Conditions: 2009 H1N1 Influenza
Interventions: Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 4 Years to 9 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza
Interventions: Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4); Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Sacramento, California • Coral Gables, Florida • Savannah, Georgia + 7 more

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 611 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more

Conditions: H1N1 Pandemic Flu
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 6 Months to 21 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza, Human
Interventions: Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1, Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1, Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1, Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 47
States / cities: Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections, H1N1 Influenza Virus
Interventions: Influenza A (H1N1) 2009 monovalent vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 25 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Birmingham, Alabama • Alhambra, California • La Jolla, California + 25 more

Conditions: Influenza
Interventions: Inactivated Influenza H1N1 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Influenza
Interventions: Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV); Biological
Lead sponsor: Novartis; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 3,604 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Downey, California • Bardstown, Kentucky + 12 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more

Conditions: Influenza
Interventions: AS03, Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more

Conditions: Influenza
Interventions: DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Influenza
Interventions: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,359 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 10
States / cities: Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: HIV Infections
Interventions: H1N1 vaccination; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: CAIV-T, TIV, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: Avian Influenza, Influenza, Influenza Immunisation
Interventions: AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine, Phosphate Buffered Saline (PBS) diluent; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more

Conditions: Influenza
Interventions: Flublok Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 9,003 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 38
States / cities: Mobile, Alabama • Tempe, Arizona • Little Rock, Arkansas + 34 more

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Nashville, Tennessee

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more

Conditions: Influenza
Interventions: cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: MF59-eH1N1; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 3 Years to 8 Years
Enrollment: 1,357 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 34
States / cities: Downey, California • Madera, California • Paramount, California + 29 more

Search by objective public record fields.

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

Influenza Vaccine in Lung Transplant Patients - Antibody

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Influenza Vaccine in Lung Transplant Patients - T Cells

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

2017 A/H7N9 IIV Revaccination

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)